Core Insights - NeuroOne Medical Technologies Corporation is addressing the needs of epilepsy patients who do not respond to traditional antiseizure medications, which affects approximately one million individuals in the U.S. alone [2][3] Company Overview - NeuroOne has developed the OneRF™ ablation system, the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously [4] - The OneRF™ system includes an electrode for monitoring brain activity, a temperature probe, and a radio frequency heat generation system, ensuring safe ablation temperatures [4][5] Innovation and Impact - The OneRF™ system allows for a single hospitalization for both electrode placement and ablation, streamlining the treatment process compared to previous methods that required multiple invasive surgeries [5][6] - A case study highlighted a teenage patient who experienced significant seizure reduction after using the OneRF™ system, demonstrating its potential effectiveness [6] Industry Context - Approximately 50 million people worldwide are affected by epilepsy, with over three million diagnosed in the U.S. [2] - NeuroOne is also exploring applications for other neurological disorders, including Parkinson's disease and chronic pain, which may improve patient outcomes and reduce procedural costs [8][9]

Core Insights - NeuroOne Medical Technologies Corporation is addressing the significant unmet need for non-pharmaceutical treatments for epilepsy, targeting the approximately one million patients who do not respond to current antiseizure medications [2][3]. Company Overview - NeuroOne has developed the OneRF™ ablation system, which is the first FDA 510(k)-cleared device capable of recording brain activity and performing RF ablation simultaneously [4]. - The OneRF™ system includes an electrode for monitoring brain activity, a temperature probe, and a radio frequency heat generation system, ensuring safe ablation temperatures [4][5]. Innovation and Impact - The OneRF™ system allows for a single hospitalization procedure, eliminating the need for multiple invasive surgeries and enabling real-time monitoring of the ablation's success [5][6]. - A case study highlighted a teenage patient who experienced significant seizure reduction after using the OneRF™ system, showcasing its potential to improve patients' quality of life [6]. Industry Context - Approximately 50 million people worldwide are affected by epilepsy, with over three million diagnosed in the US alone [2]. - The healthcare industry is increasingly focusing on innovative technologies that can provide more effective and personalized treatment options for neurological disorders [7]. Future Directions - NeuroOne is also exploring applications for other neurological conditions, including Parkinson's disease, chronic pain, and mood disorders, indicating a broader potential impact on patient care and procedural costs [9].

Core Viewpoint - NeuroOne Medical Technologies Corporation has accelerated its timeline for the 510(k) submission to the FDA for trigeminal nerve ablation, now expected in May 2025, utilizing its patented OneRF® Technology Platform, ahead of the previously projected June 2025 submission [1][3] Company Summary - NeuroOne is focused on developing minimally invasive medical technologies aimed at improving surgical care for patients with neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [4] - The company has already achieved 510(k) FDA clearance for three product families and is now advancing its OneRF Trigeminal Nerve Ablation System [3] - If FDA clearance is obtained, the company anticipates potential revenue generation from trigeminal nerve ablation by late 2025, which was not previously expected within that calendar year [3] Industry Summary - Trigeminal nerve ablation is a minimally invasive procedure that uses radiofrequency energy to alleviate severe chronic facial pain caused by trigeminal neuralgia [2] - The market for trigeminal neuralgia therapeutics, which includes both pharmacologic and surgical technologies, is projected to grow from $262 million in 2024 to over $416 million by 2030, driven primarily by an aging population [2]

EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that it will participate in the upcoming Oppenheimer 35th Annual Healthcare Conference MedTech & Services Conference on Wednesday, March 19, 2025. NeuroOne CEO Dave Rosa will host a virtual corporate presentation at 9:20 a ...

EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that it will participate in the upcoming Oppenheimer 35th Annual Healthcare Conference MedTech & Services Conference on Wednesday, March 19, 2025. NeuroOne CEO Dave Rosa will host a virtual corporate presentation at 9:20 ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Dave Rosa - CEO Ron McClurg - CFO Chris Volker - COO Operator Good day, ladies and gentlemen. Welcome to the First Quarter of Fiscal Year 2025 Financial Results Conference Call for NeuroOne Medical Technologies Corporation. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa; and Ron McClurg, the company's Chief Financial Officer. Chris Vol ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) (State or ...

Financial Performance - NeuroOne Medical Technologies Corporation announced preliminary unaudited revenue for Q1 2025, ending December 31, 2024[5] - The company has not yet completed its year-end closing and auditing procedures, indicating that actual results may differ from preliminary estimates[5] Corporate Communications - An updated corporate presentation was posted on the company's website on January 10, 2025, which may be used in future communications[7] - The forward-looking statements in the corporate presentation are based on current expectations and are subject to risks that could cause actual results to differ materially[9]

Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the first quarter fiscal year 2025 ended December 31, 2 ...

EDEN PRAIRIE, Minn., Feb. 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal first quarter ended December 31, 2024, before market open on February 12, 2025. Management will host an investor conference call and webcast at 8:30 a.m. eastern time on Wednesday, Febru ...